Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial

By sjmartinez • August 31, 2023

Moser CB, Chew KW, Ritz J, Newell M, Javan AC, Eron JJ, Daar ES, Wohl DA, Currier JS, Smith DM, Hughes MD; ACTIV-2/A5401 Study Team. Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial. J Infect Dis. 2023 Aug 31;228(Supplement_2):S92-S100. doi: 10.1093/infdis/jiad209. PMID: 37650234.

Tags: adaptive platform trials, covid-19, Harbor UCLA, Infectious Diseases, pooled placebo, Publications, randomization

SPHERES: innovative registry addressing the new era of neuromyelitis optica spectrum disorders (NMOSD) therapy

Bennett JL, Middaugh N, Yeaman MR, Smith TJ, Behne MK, Crabtree M, McLean RR, Pappas DA, Levy M. SPHERES: innovative registry addressing the new era[...]

Less Inflammatory Debris, Improved Immunity from Immune Detox: A New Perspective on the Benefits of Exercise in Chronic Disease

Abbasi A, Stringer W. Less Inflammatory Debris, Improved Immunity from Immune Detox: A New Perspective on the Benefits of Exercise in Chronic Disease. Exerc Immunol[...]

Next-generation Candida albicans vaccine VXV-01 containing recombinant Als3p and Hyr1p antigens for invasive Candida infections

Singh S, Youssef EG, Barbarino A, Hautau H, Nabeela S, Gebremariam T, Alkhazraji S, Ostroff G, Christensen D, Cochrane T, Ibrahim AS. Next-generation Candida albicans[...]